Texting & Phone Counseling Support Program for Breast Cancer Patients Receiving Hormone Therapy

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

a study on Breast Cancer Hormone Receptor Positive Breast Cancer Carcinoma

Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Judy M. Cheng (ucsf)

Description

Summary

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.

Official Title

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Details

PRIMARY OBJECTIVES:

  1. Compare endocrine therapy (ET) adherence at 12 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.

SECONDARY OBJECTIVES:

  1. Compare endocrine therapy (ET) adherence at 24 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I (TMR): Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.

ARM II (MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.

ARM III (TMR + MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.

ARM IV (ENHANCED USUAL CARE): Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.

After completion of study participation, patients are followed up for up to 24 months.

Keywords

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Carcinoma, Breast Neoplasms, Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Quality-of-Life Assessment, TMR + MI

Eligibility

For females ages 18 years and up

  • Women with an initial pathologically confirmed diagnosis of stage I-III, hormone receptor positive, HER2-neu negative, invasive breast cancer within 18 months prior to enrollment
    • Women who have undergone neo-adjuvant chemotherapy who have no residual invasive disease post-surgery are eligible based on an initial pathologically confirmed diagnosis
    • Hormone receptor positive is defined as estrogen receptor (ER) and/or progesterone receptor (PR) of > 1%
    • HER2-neu negative is defined as 0-1+ by immunohistochemical (IHC) analysis, or non-amplified by fluorescence in situ hybridization (FISH) analysis
  • Patients must have received cancer-directed surgery, and/or completed all other adjuvant therapy, except reconstruction
  • Patients must have initiated an endocrine therapy drug within the 6 months prior to registration, OR have received a prescription with stated intent to initiate within 6 weeks after registration
  • No history of previous cancer as follows:
    • Invasive or non-invasive breast cancer at any time
    • Non-breast cancer, within the past 5 years, excluding non-melanoma skin cancer
  • Patients must be willing to use a smart phone for study activities
    • Patient is NOT to be deemed ineligible during the recruitment process if they do not have a smart phone
    • If a participant does not own a smart phone or has limited data or texting capabilities or their smart phone cannot support the Alliance electronic patient reported outcomes (ePRO) survey application (app), a smart phone and service can be provided to the participant at no cost through the Ohio State University (OSU) partnership with Verizon Wireless for the duration of the study activities
    • The CRP is ONLY to discuss this option with those patients who self-identify a phone-related barrier to participation, including: lack of a smart phone, insufficient phone plan (minutes/text/data), or a smart phone incompatible with the Alliance ePRO app
    • For OSU -provided phones, charges will be paid by the grant through the intervention period. At the end of the 12-month intervention period, patients will be responsible for paying monthly fees, if continued service is desired. The physical phones will belong to the patients at the end of their study activities
  • Patients must be willing to use a Pillsy medication event monitoring system for the duration of study participation
  • In order to complete the mandatory patient-completed measures, participants must be able to speak and read English

Locations

  • UCSF Cancer Center - Berkeley accepting new patients
    Berkeley California 94702 United States
  • Zuckerberg San Francisco General Hospital currently not accepting new patients, but might later
    San Francisco California 94110 United States
  • UCSF Cancer Center - San Mateo accepting new patients
    San Mateo California 94402 United States
  • Saint John's Cancer Institute accepting new patients
    Santa Monica California 90404 United States
  • Kaiser Permanente-San Francisco accepting new patients
    San Francisco California 94115 United States
  • Kaiser Permanente West Los Angeles accepting new patients
    Los Angeles California 90034 United States
  • Kaiser Permanente-Fresno accepting new patients
    Fresno California 93720 United States
  • Kaiser Permanente-South San Francisco accepting new patients
    South San Francisco California 94080 United States
  • Kaiser Permanente-Irvine accepting new patients
    Irvine California 92618 United States
  • Kaiser Permanente Los Angeles Medical Center accepting new patients
    Los Angeles California 90027 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Alliance for Clinical Trials in Oncology
ID
NCT04379570
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1180 study participants
Last Updated